[1]CurrentPatentAssignee:EFFECTORTHERAPEUTICSINC-US2020/131179,2020,A1
[1]CurrentPatentAssignee:EFFECTORTHERAPEUTICSINC-US2020/131179,2020,A1
[1]CurrentPatentAssignee:EFFECTORTHERAPEUTICSINC-US2020/131179,2020,A1Locationinpatent:Paragraph0095;0099-0100
[1]CurrentPatentAssignee:WUHANJIUZHOUYUMINPHARMACEUTICALTECH-CN114736205,2022,ALocationinpatent:Paragraph0052;0083-0089
[1]CurrentPatentAssignee:WUHANJIUZHOUYUMINPHARMACEUTICALTECH-CN114736205,2022,A
Title: Kevin R. Webster, et al. eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL). Blood 2015 126:1554.
Title: Xu Y, et al. Translation control of the immune checkpoint in cancer and its therapeutic targeting. Nat Med. 2019 Feb;25(2):301-311.